|Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient|
Paul G. Richardson, MD
|Release Date: October 29, 2018|
Expiration Date: October 29, 2019
With many new and emerging drug classes for the treatment of relapsed/refractory multiple myeloma (RRMM), it can be challenging to determine the optimal approach to sequencing treatment for patients with the disease. This activity will compare efficacy and safety data on new and emerging therapies in RRMM and provide strategies for incorporating risk-adapted treatment decisions to optimize patient outcomes.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|